Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Improved knowledge of local epidemiology and predicting risk factors of multidrug-resistant (MDR) bacteria are required to optimize the management of infections. This study examined local epidemiology and antibiotic resistance patterns of liver cirrhosis (LC) patients and evaluated the predictors of MDR bacteremia in Korea. Methods: This was a retrospective study including 140 LC patients diagnosed with bacteremia between January 2017 and December 2022. Local epidemiology and antibiotic resistance patterns and the determinants of MDR bacteremia were analyzed using logistic regression analysis. Results: The most frequently isolated bacteria, from the bloodstream, were Escherichia coli (n = 45, 31.7%) and Klebsiella spp. (n = 35, 24.6%). Thirty-four isolates (23.9%) were MDR, and extended-spectrum beta-lactamase E. coli (52.9%) and methicillin-resistant Staphylococcus aureus (17.6%) were the most commonly isolated MDR bacteria. When Enterococcus spp. were cultured, the majority were MDR (MDR 83.3% vs. 16.7%, p = 0.003), particularly vancomycin-susceptible Enterococcus faecium. Antibiotics administration within 30 days and/or nosocomial infection was a significant predictor of MDR bacteremia (OR: 3.40, 95% CI: 1.24–9.27, p = 0.02). MDR bacteremia was not predicted by sepsis predictors, such as positive systemic inflammatory response syndrome (SIRS) or quick Sequential Organ Failure Assessment (qSOFA). Conclusions: More than 70% of strains that can be treated with a third-generation cephalosporin have been cultured. In cirrhotic patients, antibiotic administration within 30 days and/or nosocomial infection are predictors of MDR bacteremia; therefore, empirical administration of broad-spectrum antibiotics should be considered when these risk factors are present.
Abstract
Background/Aims: Improved knowledge of local epidemiology and predicting risk factors of multidrug-resistant (MDR) bacteria are required to optimize the management of infections. This study examined local epidemiology and antibiotic resistance patterns of liver cirrhosis (LC) patients and evaluated the predictors of MDR bacteremia in Korea. Methods: This was a retrospective study including 140 LC patients diagnosed with bacteremia between January 2017 and December 2022. Local epidemiology and antibiotic resistance patterns and the determinants of MDR bacteremia were analyzed using logistic regression analysis. Results: The most frequently isolated bacteria, from the bloodstream, were Escherichia coli (n = 45, 31.7%) and Klebsiella spp. (n = 35, 24.6%). Thirty-four isolates (23.9%) were MDR, and extended-spectrum beta-lactamase E. coli (52.9%) and methicillin-resistant Staphylococcus aureus (17.6%) were the most commonly isolated MDR bacteria. When Enterococcus spp. were cultured, the majority were MDR (MDR 83.3% vs. 16.7%, p = 0.003), particularly vancomycin-susceptible Enterococcus faecium. Antibiotics administration within 30 days and/or nosocomial infection was a significant predictor of MDR bacteremia (OR: 3.40, 95% CI: 1.24–9.27, p = 0.02). MDR bacteremia was not predicted by sepsis predictors, such as positive systemic inflammatory response syndrome (SIRS) or quick Sequential Organ Failure Assessment (qSOFA). Conclusions: More than 70% of strains that can be treated with a third-generation cephalosporin have been cultured. In cirrhotic patients, antibiotic administration within 30 days and/or nosocomial infection are predictors of MDR bacteremia; therefore, empirical administration of broad-spectrum antibiotics should be considered when these risk factors are present.
참고문헌 (31)
- Shankar N, "Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017", Ann Hepatol, 26, pp.100565~ (2021)
- Thulstrup AM, "Population-based study of the risk and shortterm prognosis for bacteremia in patients with liver cirrhosis", Clin Infect Dis, 31, pp.1357~1361 (2000)
- Bartoletti M, "Bloodstream infections in patients with liver cirrhosis", Virulence, 7, pp.309~319 (2016)
- Piano S, "Changes in the epidemiology and management of bacterial infections in cirrhosis", Clin Mol Hepatol, 27, pp.437~445 (2021)
- Arvaniti V, "Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis", Gastroenterology, 139, pp.1246~1256 (2010)
- Fernández J, "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis : a prospective study", Hepatology, 55, pp.1551~1561 (2012)
- Bartoletti M, "Epidemiology and outcomes of bloodstream infection in patients with cirrhosis", J Hepatol, 61, pp.51~58 (2014)
- Piano S, "Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide", Gastroenterology, 156, pp.1368~1380 (2019)
- Addo Smith JN, "Bacteremia in patients with liver cirrhosis : prevalence and predictors of multidrug resistant organisms", J Clin Gastroenterol, 52, pp.648~654 (2018)
- Milovanovic T, "Bacteremia in patients with liver cirrhosis in the era of increasing antimicrobial resistance : single-center epidemiology", J Infect Dev Ctries, 15, pp.1883~1890 (2021)
- Johnson AL, "Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis : a population-based study", BMJ Open Gastroenterol, 8, pp.e000695~ (2021)
- Tandon P, "High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center", Clin Gastroenterol Hepatol, 10, pp.1291~1298 (2012)
- Milovanovic T, "Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis : single center experience in Serbia", BMC Infect Dis, 19, pp.141~ (2019)
- Kuo CH, "Bacteremia in patients with cirrhosis of the liver", Liver, 11, pp.334~339 (1991)
- Kamath PS, "A model to predict survival in patients with end-stage liver disease", Hepatology, 33, pp.464~470 (2001)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Fernández J, "Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe", J Hepatol, 70, pp.398~411 (2019)
- Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP", SCCM Consensus Conference Committee. American College of Chest Physicians, Chest, pp.1992, 101[DOI]
- Singer M, "The third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Friedman ND, "Health care--associated bloodstream infections in adults : a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Chen SY, "Impact of liver cirrhosis on mortality in patients with community-acquired bacteremia", Diagn Microbiol Infect Dis, 64, pp.124~130 (2009)
- Kang CI, "Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia", J Infect, 63, pp.336~343 (2011)
- Fernández J, "Bacterial infections in cirrhosis : epidemiological changes with invasive procedures and norfloxacin prophylaxis", Hepatology, 35, pp.140~148 (2002)
- Xie Y, "Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis", Sci Rep, 7, pp.11482~ (2017)
- Kim JH, "Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department : A multicenter study", Clin Mol Hepatol, 28, pp.540~552 (2022)
- Siegel JD, "Management of multidrug-resistant organisms in health care settings, 2006", Am J Infect Control, 35(10 Suppl 2), pp.S165~S193 (2007)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis", J Hepatol, 69, pp.406~460 (2018)
- Arabi YM, "Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis", Hepatology, 56, pp.2305~2315 (2012)
- Moreau R, "Septic shock in patients with cirrhosis : hemodynamic and metabolic characteristics and intensive care unit outcome", Crit Care Med, 20, pp.746~750 (1992)
- "American College of Chest Physicians", Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, 1992, pp.20, 864~874
- Son J, "The quick sepsis-related organ failure score has limited value for predicting adverse outcomes in sepsis patients with liver cirrhosis", Korean J Intern Med, 35, pp.861~872 (2020)